Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

How do cancer-related mutations affect the oligomerisation state of the p53 tetramerisation domain?

  • Nicolini, Federica
  • Todorovski, Toni
  • Puig, Eduard
  • Díaz-Lobo, Mireia
  • Vilaseca, Marta
  • García, Jesús
  • Andreu Martínez, David
  • Giralt, Ernest
Tumour suppressor p53 plays a key role in the development of cancer and has therefore been widely studied in recent decades. While it is well known that p53 is biologically active as a tetramer, the tetramerisation mechanism is still not completely understood. p53 is mutated in nearly 50% of cancers, and mutations can alter the oligomeric state of the protein, having an impact on the biological function of the protein and on cell fate decisions. Here, we describe the effects of a number of representative cancer-related mutations on tetramerisation domain (TD) oligomerisation defining a peptide length that permits having a folded and structured domain, thus avoiding the effect of the flanking regions and the net charges at the N- and C-terminus. These peptides have been studied under different experimental conditions. We have applied a variety of techniques, including circular dichroism (CD), native mass spectrometry (MS) and high-field solution NMR. Native MS allows us to detect the native state of complexes maintaining the peptide complexes intact in the gas phase; the secondary and quaternary structures were analysed in solution by NMR, and the oligomeric forms were assigned by diffusion NMR experiments. A significant destabilising effect and a variable monomer population were observed for all the mutants studied., This research was funded by MINECO-FEDER (BIO 2016-75327-R).
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

A Site-Specific MiniAp4–Trastuzumab Conjugate Prevents Brain Metastasis

  • Al-Masmudi Martín, Mariam
  • Oller-Salvia, Benjamí
  • Perea Villena, María Jesús
  • teixido, meritxell
  • Valiente, Manuel
  • giralt, ernest
  • Sanchez-Navarro, Macarena
Monoclonal antibodies (mAbs) are changing cancer treatments. However, the presence of the blood–brain barrier (BBB) and the blood–tumor barrier (BTB) limits the use of mAbs to treat brain cancer or brain metastasis. Molecules that hijack endogenous transport mechanisms on the brain endothelium (brain shuttles) have been shown to increase the transport of large molecules and nanoparticles across the BBB. Among these shuttles, protease-resistant peptides such as MiniAp-4 are particularly efficient. Here, we report the synthesis, characterization, and evaluation of site-specific mAb–brainshuttle antibody conjugates (ASC) based on the anti-HER2 mAb trastuzumab (Tz) and four molecules of MiniAp-4. The ASCs preserve the binding and cell cycle arrest capacity of Tz. MiniAp-4 ASC displays enhanced transport across an in vitro BBB cellular model with respect to Tz and Tz conjugated to Angiopep-2, the brain shuttle that has advanced the most in clinical trials. More importantly, evaluation of Tz-MiniAp4 in a murine brain metastasis model demonstrated that the protease-resistant peptide showed preferential transport across the BBB/BTB, displaying a marked therapeutic effect and protecting against metastasis development. The technology described herein could be applied to any antibody of interest to treat central nervous system-related diseases. MiniAp-4 enhances the brain transport of the monoclonal antibody trastuzumab, preventing brain metastasis., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Target-templated de novo design of macrocyclic D-/L-peptides: discovery of drug-like inhibitors of PD-1

  • Guardiola, Salvador
  • Varese, Mónica
  • Roig, Xavier
  • Sánchez-Navarro, Macarena
  • García, Jesús
  • Giralt, Ernest
Peptides are a rapidly growing class of therapeutics with various advantages over traditional small molecules, especially for targeting difficult protein¿protein interactions. However, current structure-based methods are largely limited to natural peptides and are not suitable for designing bioactive cyclic topologies that go beyond natural L-amino acids. Here, we report a generalizable framework that exploits the computational power of Rosetta, in terms of large-scale backbone sampling, side-chain composition and energy scoring, to design heterochiral cyclic peptides that bind to a protein surface of interest. To showcase the applicability of our approach, we developed two new inhibitors (PD-i3 and PD-i6) of programmed cell death 1 (PD-1), a key immune checkpoint in oncology. A comprehensive biophysical evaluation was performed to assess their binding to PD-1 as well as their blocking effect on the endogenous PD-1/PD-L1 interaction. Finally, NMR elucidation of their in-solution structures confirmed our de novo design approach., This study was funded by MINECO-FEDER (BIO 2016-75327-R) and the Generalitat de Catalunya (XRB and 2017SGR-998). We thank the NMR Facility, Dr M. Taulés (CCiT-UB) and the MS Core Facility (IRB Barcelona) for their technical support. We also acknowledge the computer resources at Mare Nostrum and the technical support provided by the Barcelona Supercomputing Center (BCV-2018-1-0005). We are grateful to Prof Tad Holak for providing the PD-1 plasmid and to Dr E. Marcos for useful discussions. IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood–brain barrier transport

  • Díaz-Perlas, Cristina
  • Oller-Salvia, Benjamí
  • Sánchez-Navarro, Macarena
  • Teixidó, Meritxell
  • Giralt, Ernest
The blood–brain barrier (BBB) hampers the delivery of therapeutic proteins into the brain. BBB-shuttle peptides have been conjugated to therapeutic payloads to increase the permeability of these molecules. However, most BBB-shuttles have several limitations, such as a lack of resistance to proteases and low effectiveness in transporting large biomolecules. We have previously reported on the THRre peptide as a protease-resistant BBB-shuttle that is able to increase the transport of fluorophores and quantum dots in vivo. In this work, we have evaluated the capacity of linear and branched THRre to increase the permeability of proteins in cellular models of the BBB. With this purpose, we have covalently attached peptides with one or two copies of the BBB-shuttle to proteins in order to develop chemically well-defined peptide–protein conjugates. While THRre does not enhance the uptake and transport of a model protein in BBB cellular models, branched THRre peptides displaying two copies of the BBB-shuttle result in a 2.6-fold increase., This work was funded by MINECO-FEDER (BIO2016-75327-R), RecerCaixa-2014-Gate2Brain and Generalitat de Catalunya (XRB, 2017SGR0998 and 2016PROD00087 – this project has been nanced with European Fund of Regional Development (FEDER)). We thank FEDAES/GENEFA and ASOGAF/BABEL FAMILY for support. IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence fromMINECO (Government of Spain) and the CERCA Programme of the Catalan Government. C. D.-P. holds a Predoctoral Grant Severo Ochoa (SVP-2013-067740)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NIR and glutathione trigger the surface release of methotrexate linked by Diels-Alder adducts to anisotropic gold nanoparticles

  • Bolaños, Karen
  • Sánchez-Navarro, Macarena
  • Giralt, Ernest
  • Acosta, Gerardo
  • Albericio, Fernando
  • Kogan, Marcelo J.
  • Araya, Eyleen
The administration and controlled release of drugs over time remains one of the greatest challenges of science today. In the nanomaterials field, anisotropic gold nanoparticles (AuNPs) with plasmon bands centered at the near-infrared region (NIR), such as gold nanorods (AuNRs) and gold nanoprisms (AuNPrs), under laser irradiation, locally increase the temperature, allowing the release of drugs. In this sense, temporally controlled drug delivery could be promoted by external stimuli using thermo-reversible chemical reactions, such as Diels-Alder cycloadditions from a diene and a dienophile fragment (compound a). In this study, an antitumor drug (methotrexate, MTX) was linked to plasmonic AuNPs by a Diels-Alder adduct (compound c), which after NIR suffers a retro-Diels-Alder reaction, producing release of the drug (compound b). We obtained two nanosystems based on AuNRs and AuNPrs. Both nanoconstructs were coated with BSA-r8 (Bovine Serum Albumin functionalized with Arg8, all-D octa arginine) in order to increase the colloidal stability and promote internalization of the nanosystems on HeLa and SK-BR-3 cells. In addition, the presence of BSA allows protecting the cargo from being released on the extracellular environment and promotes the photothermal release of the drug in the presence of glutathione (GSH). The nanosystems' drug release profile was evaluated after NIR irradiation in the presence and absence of glutathione (GSH), showing a considerable increase of drug release when NIR light and glutathione were combined. This work broadens the range of possibilities of using two complementary strategies for the controlled release of an antitumor drug from AuNRs and AuNPrs: the photothermal cleavage of a thermolabile adduct controlled by an external stimulus (laser irradiation), complemented with the use of the intracellular metabolite GSH., The authors acknowledge the financial support of ANID, Chile: KB acknowledges to Doctoral fellowship 21180258 and Advanced Center for Chronic Diseases. EA acknowledges to Fondecyt 1190623. MK acknowledges to FONDECYT 1211482 and FONDAP 15130011. EG and MS acknowledge to MINECO-FEDER (BIO 2016-75327-R), to the Generalitat de Catalunya (XRB and 2017SGR-998) and IRB Barcelona, which is the recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain). GA thanks to Nambiosis-CIBER-BBN peptide synthesis (unit 3) for the collaboration in this study. The authors acknowledge the support of the IRB Advanced Microscopy Core Facility and Electronic Microscopy Facility from Centres Científics i Tecnològics Universitat de Barcelona., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Blocking EGFR Activation with Anti-EGF Nanobodies via Two Distinct Molecular Recognition Mechanisms

  • Guardiola, Salvador
  • Varese, Monica
  • Sánchez-Navarro, Macarena
  • Vincke, Cécile
  • Teixidó, Meritxell
  • García, Jesús
  • Muyldermans, Serge
  • Giralt, Ernest
One of the hallmarks of cancer is the overproduction of growth factors such as EGF. Despite the clinical success achieved by EGFR-targeted therapies, their long-term efficacy is compromised by the onset of drug-resistant mutations. To address this issue, a family of camelid-derived single-domain antibodies (Nbs) were generated, obtaining the first direct EGF inhibitors that prevent EGFR phosphorylation and pathway activation through this new mechanism of action. The two best Nbs were subjected to a detailed investigation of their interaction mechanism that revealed important differences in their binding kinetics and equilibrium thermodynamics. These distinct behaviors at the biophysical level translate into an equally efficient inhibition of the cellular EGFR phosphorylation, thus proving the efficacy of these Nbs to turn off the initiation of this key oncogenic pathway in cancer cells., This study was funded by MINECO-FEDER (BIO 2016-75327-R) and Generalitat de Catalunya (XRB and 2017SGR-998). We thank the NMR facility from Scientific and Technological Centre of the University of Barcelona (CCiT-UB) and the Mass Spectrometry Core Facility (IRB Barcelona) for their technical support. IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

How do cancer-related mutations affect the oligomerisation state of the p53 tetramerisation domain?

  • Nicolini, Federica
  • Todorovski, Toni
  • Puig, Eduard
  • Díaz-Lobo, Mireia
  • Vilaseca, Marta
  • García, Jesús
  • Andreu Martínez, David
  • Giralt, Ernest
Tumour suppressor p53 plays a key role in the development of cancer and has therefore been widely studied in recent decades. While it is well known that p53 is biologically active as a tetramer, the tetramerisation mechanism is still not completely understood. p53 is mutated in nearly 50% of cancers, and mutations can alter the oligomeric state of the protein, having an impact on the biological function of the protein and on cell fate decisions. Here, we describe the effects of a number of representative cancer-related mutations on tetramerisation domain (TD) oligomerisation defining a peptide length that permits having a folded and structured domain, thus avoiding the effect of the flanking regions and the net charges at the N- and C-terminus. These peptides have been studied under different experimental conditions. We have applied a variety of techniques, including circular dichroism (CD), native mass spectrometry (MS) and high-field solution NMR. Native MS allows us to detect the native state of complexes maintaining the peptide complexes intact in the gas phase; the secondary and quaternary structures were analysed in solution by NMR, and the oligomeric forms were assigned by diffusion NMR experiments. A significant destabilising effect and a variable monomer population were observed for all the mutants studied., This research was funded by MINECO-FEDER (BIO 2016-75327-R).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A Site-Specific MiniAp4–Trastuzumab Conjugate Prevents Brain Metastasis

  • Al-Masmudi Martín, Mariam
  • Oller-Salvia, Benjamí
  • Perea Villena, María Jesús
  • teixido, meritxell
  • Valiente, Manuel
  • giralt, ernest
  • Sanchez-Navarro, Macarena
Monoclonal antibodies (mAbs) are changing cancer treatments. However, the presence of the blood–brain barrier (BBB) and the blood–tumor barrier (BTB) limits the use of mAbs to treat brain cancer or brain metastasis. Molecules that hijack endogenous transport mechanisms on the brain endothelium (brain shuttles) have been shown to increase the transport of large molecules and nanoparticles across the BBB. Among these shuttles, protease-resistant peptides such as MiniAp-4 are particularly efficient. Here, we report the synthesis, characterization, and evaluation of site-specific mAb–brainshuttle antibody conjugates (ASC) based on the anti-HER2 mAb trastuzumab (Tz) and four molecules of MiniAp-4. The ASCs preserve the binding and cell cycle arrest capacity of Tz. MiniAp-4 ASC displays enhanced transport across an in vitro BBB cellular model with respect to Tz and Tz conjugated to Angiopep-2, the brain shuttle that has advanced the most in clinical trials. More importantly, evaluation of Tz-MiniAp4 in a murine brain metastasis model demonstrated that the protease-resistant peptide showed preferential transport across the BBB/BTB, displaying a marked therapeutic effect and protecting against metastasis development. The technology described herein could be applied to any antibody of interest to treat central nervous system-related diseases. MiniAp-4 enhances the brain transport of the monoclonal antibody trastuzumab, preventing brain metastasis., info:eu-repo/semantics/publishedVersion